Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02181 MABPHARM-B
RT Nominal unchange0.335 0.000 (0.000%)
Latest  |  Final  |  Interim
Non-current Assets
2023/12 - Final
RMB(K¥)
%Chg
(Compare to Final)
2022/12
RMB(K¥)
2021/12
RMB(K¥)
2020/12
RMB(K¥)
2019/12
RMB(K¥)
Investment Properties0--0000
Property, plant, equip. & others615,232-3.312%636,306483,673438,408255,049
Land & other Lease Assets71,3045.313%67,70777,37474,20977,346
Intangible Assets0--0000
Interests in Asso. & JCEs0--0000
Other Non-current Assets6,231-49.701%12,38891,08581,294108,943

692,767-3.299%716,401652,132593,911441,338
Current Assets
2023/12 - Final
RMB(K¥)
%Chg
(Compare to Final)
2022/12
RMB(K¥)
2021/12
RMB(K¥)
2020/12
RMB(K¥)
2019/12
RMB(K¥)
Inventories102,0371.230%100,79753,21133,42722,224
Trade Receivables19,423103.766%9,53279300
Cash & Bank Balances173,345416.400%33,56881,556484,846588,720
Other Current Assets47,401-17.164%57,223112,21050,853344,195
Assets Held for Sale0--0000

342,20670.150%201,120247,770569,126955,139
Current Liabilities
2023/12 - Final
RMB(K¥)
%Chg
(Compare to Final)
2022/12
RMB(K¥)
2021/12
RMB(K¥)
2020/12
RMB(K¥)
2019/12
RMB(K¥)
Trade Payables10,012-39.636%16,58612,8604,4664,401
S-T Debt & Leases125,258842.427%13,2919,2838,53270,500
Other Current Liabilities180,92114.128%158,524212,861189,629195,433
Liab asso w/ Assets Held for Sale0--0000

316,19167.829%188,401235,004202,627270,334
Net Current Assets26,015104.537%12,71912,766366,499684,805
Total Assets Less Current Liabilities718,782-1.418%729,120664,898960,4101,126,143
Non-current Liabilities
2023/12 - Final
RMB(K¥)
%Chg
(Compare to Final)
2022/12
RMB(K¥)
2021/12
RMB(K¥)
2020/12
RMB(K¥)
2019/12
RMB(K¥)
L-T Debt & Leases134,81519.257%113,04636,40731,81635,123
Other Non-current Liabilities378,91076.131%215,13026,51047,10937,309

513,72556.539%328,17662,91778,92572,432
Capital and Reserves
2023/12 - Final
RMB(K¥)
%Chg
(Compare to Final)
2022/12
RMB(K¥)
2021/12
RMB(K¥)
2020/12
RMB(K¥)
2019/12
RMB(K¥)
  Share Capital2,8040.000%2,8042,8042,8042,804
  Reserves202,253-49.201%398,140599,177878,6811,050,907
  Others0--0000
Shareholders' Funds205,057-48.856%400,944601,981881,4851,053,711
Non-controlling Interests0--0000
Others0--0000

205,057-48.856%400,944601,981881,4851,053,711
Commitments and Contingent Liabilities
2023/12 - Final
RMB(K¥)
%Chg
(Compare to Final)
2022/12
RMB(K¥)
2021/12
RMB(K¥)
2020/12
RMB(K¥)
2019/12
RMB(K¥)
Commitments3,978-80.838%20,760138,649138,014182,332
Contingent Liabilities0--0000
Remarks:  Real time quote last updated: 01/11/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
Security Code
Company Name (Chi/Eng/Keywords)
Industry
Profit / (Loss) Attributable to Shareholders (¥)RMB -97,569,000
%Change-2.430%
EPS / (LPS)RMB -0.020
NBV Per Share (¥)RMB 0.028
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.